Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 4
Submit an article Journal homepage
47
Views
5
CrossRef citations to date
0
Altmetric
Review

Cost-effectiveness studies of diabetes prevention in high-risk patients

Andrew J Palmer Center for Outcomes Research, Buendtenmattstrasse 40, 4102 Binningen, Basel, Switzerland. [email protected]
,
William J Valentine Center for Outcomes Research, Buendtenmattstrasse 40, 4102 Binningen, Basel, Switzerland. [email protected]
&
Joshua A Ray Center for Outcomes Research, Buendtenmattstrasse 40, 4102 Binningen, Basel, Switzerland. [email protected]
Pages 393-402 | Published online: 09 Jan 2014

References

  • Harris MI, Regal KM, Cowie CC et al Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Cate 21(4), 518–524 (1998).
  • Takiya L, Chawla S. Therapeutic options for the management of Type 2 diabetes mellitus. Am.j Managed Cate 8(11), 1009–1023 (2002).
  • Uusitupa M, Siitonen O, Aro A, Pyorala K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed Type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 28(1), 22–27 (1985).
  • Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Cate 16(4), 642–652 (1993).
  • Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl. J. Med. 333(2), 89–94 (1995).
  • UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998).
  • UKPDS Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
  • Harris MI, Eastman RC. Early detection of undiagnosed diabetes mellitus: a USperspective. Diabetes Metab. Res. Rev. 16(4), 230–236 (2000).
  • Pan XR, Li GW, Hu YH et al Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Cate 20(4), 537–544 (1997).
  • Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl. J. Med. 344(18), 1343–1350 (2001).
  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Looks° M. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323), 2072-2077 (2002).
  • Knowler WC, Barrett-Connor E, Fowler SE et al Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engif Med. 346(6), 393–403 (2002). Describes the findings of the Diabetes Prevention Program (DPP) trial.
  • DECODE Study Group. Age- and sex- specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26(1), 61–69 (2003).
  • Dunstan DW, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25(5), 829–834 (2002).
  • Karpova L, Zalevskaya A, Bregovsky B. The effect of diet and physical training in patients with impaired glucose tolerance: 2 year follow-up. EASD 38th Annual Meeting-of the European Association for the Studies of Diabetes Budapest, Hungary. Abstract 316 (2002).
  • Chiasson JL, Josse RG, Gomis R. Acarbose can prevent Type 2 diabetes and cardiovascular disease in subjects with imparied glucose tolerance: the STOP-NIDDM Trial. EA SD Annual meeting of the European Association for the Study of Diabetes. Budapest Hungary. Abstract 312 (2002).
  • Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care 27(1), 155–161 (2004).
  • Hannover Consensus Group. German recommendations for healthcare economic evaluation studies. Revised version of the Hannover consensus. Med. 'Gin. 95(1), 52–55 (2000).
  • Hannoverian Consensus Group. German recommendations for health economic evaluation. Revised edition of the Hannoverian consensus. Dtsch. Med Wochenschr 124(49), 1503–1506 (1999).
  • Detsky AS. Using cost-effectiveness analysis for formulary decision making: from theory into practice. PharmacoEconomics 6(4), 281–288 (1994).
  • Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146(4), 473–481 (1992).
  • Mason J, Drummond M, Torrance G. Some guidelines on the use of cost-effectiveness league tables. BE Med. J. 306(6877), 570–572 (1993).
  • Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAIVIA 276(16), 1339–1341 (1996).
  • Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAIVIA 276(15), 1253–1258 (1996).
  • Pharmaceutical Benefits Advisory Committee. Guidelines for the pharmaceutical industry on preparation of submissions to the PBAC. (2002).
  • Sullivan SD, Lyles A, Luce B et al. AMCP guidelines for submission of clinical and economic evaluation data to support formulary listing in the US health plans and pharmacy benefits management organizations. J. Managed Care Pharm. 7, 272–282 (2001).
  • Herman WH, Brandle M, Zhang P et al. Costs associated with the primary prevention of Type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 26(1), 36–47 (2003). Outlines the costs and short-term cost-effectiveness analysis from the DPP
  • Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of Type 2 diabetes. Diabetes Care 26 (9), 2518–2523 (2003) . Outlines the costs and short-term cost-effectiveness analysis from the DPP
  • Palmer AJ, Roze S, Valentine W, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in subjects with impaired glucose tolerance: modelling the long-term health economic implications of the Diabetes Prevention Program in the Australian, French, German, Swiss and UK settings. Clin. Ther 26(2), 304–21 (2004). Describes the long-term international cost-effectiveness analysis based on the DPP findings.
  • Palmer AJ, Roze S. Prevention of Type 2 diabetes in the USA: cost-effectiveness issues. Value Health 5 (3), 204 (2002) .
  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Looks° M. Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323), 2072-2077 (2002).
  • Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Looks° M. The STOP-NIDDM Trial: an international study on the efficacy of an a-glucosidase inhibitor to prevent Type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to prevent non-insulin-dependent diabetes mellitus. Diabetes Care 21(10), 1720–1725 (1998).
  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Looks° M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM tria1.161/1//A 290(4), 486–494 (2003).
  • Wenying Y, Lixiang L, Jinwu Q, Guangwei L, Zhiqing Y, Xiaoren P. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3 year multicentral prospective study. Chinesef Endocrinol. Metab. (17), 131–134 (2001).
  • Durbin RJ. Thiazolidinedione therapy in the prevention/delay of Type 2 diabetes in patients with insulin resistance and imparied glucose tolerance. EASD 38th Annual meeting of the Eumpean Association for the Study of Diabetes. Budapest, Hungary. Abstract 314 (2002).
  • Haffner S, Hotman R, Califf RM, McMurray J, Pecher E. Targeting post-prandial hyperglycemia to prevent Type 2 diabetes: rationale and design of the navigator trial. EASD 38th Annual meeting of the European Association for the Stuch, of Diabetes. Budapest, Hungary. Abstract 319 (2004).
  • McAuley IKA, Williams SM, Mann JI et al Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial. Diabetes Care 25 (3), 445–452 (2002).
  • Pate RR, Pratt M, Blair SN et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of sports med. JAIVIA 273(5), 402–407 (1995).
  • Krauss RM, Eckel RII, Howard B et al. Revision (2000) a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Nut. 131 (1), 132–146 (2001).
  • Hanefeld M, Josse RG, Gomis R, Karasik A, Looks° M, Chaisson J-L. Efficacy of acarbose to prevent Type 2 diabetes is different in subgroups of subjects with impaired glucose tolerance: the STOP-NIDDM Trial. EASD 38th Annual meeting of the European Association for the Stuch, of Diabetes. Budapest, Hungary. Abstract 313 (2002).
  • Freeman DJ, Norrie J, Sattar N et al Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103(3), 357–362 (2001).
  • Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents Type 2 diabetes by formation of fat cells. Hypertension 40 (5), 609–611 (2002) .
  • Lonn E, Yusuf S, Hoogwerf B et al Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care25(11), 1919–1927 (2002).
  • Padwal R, Laupacis A. Antihypertensive therapy and incidence of Type 2 diabetes: a systematic review. Diabetes Care 27(1), 247–255 (2004).

Websites

  • National Institute for Clinical Excellence. Guide to the technology appraisal process www.nice.org.uk/pdf-technologyappraisalprocessflnal.pdf (Accessed July 2004)
  • www.core-dppmodel.com (Accessed July 2004)
  • Diabetes Prevention Program Summary www.niddk.nih.gov/welcome/releases/ 8_8_01.htm (Accessed July 2004)
  • Complete results of cost-effectiveness analysis of the DPP in the Australian, French, German, Swiss,, and UK settings, including sub-group analyses and sensitivity analyses www.thecenter.ch/dpp-sensitivity-analysis/ (Accessed July 2004)
  • STOP-NIDDM trial website www.stop-niddm.com (Accessed July 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.